HRMY · Insider Trading
Harmony Biosciences Holdings, Inc. Common Stock
Every open-market purchase and sale reported by HRMY officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-18 | Kumar Budur | CHIEF MEDICAL OFFICER | MIXED | — | −$486.56K |
| 2026-09-09 | Kumar Budur | CHIEF MEDICAL OFFICER | MIXED | −11,000 | −$753.23K |
| 2026-05-18 | Linda M Szyper | Director | A | +21,872 deriv. | — |
| 2026-05-18 | Geno J Germano | Director | A | +21,231 deriv. | — |
| 2026-05-18 | Juan A. Sabater | Director | A | +21,872 deriv. | — |
| 2026-05-18 | Gary Sender | Director | A | +21,872 deriv. | — |
| 2026-05-18 | R. Mark Graf | Director | A | +21,872 deriv. | — |
| 2026-05-18 | Kumar Budur | CHIEF MEDICAL OFFICER | MIXED | +9,868 | −$282.71K |
| 2026-05-18 | Ron M Philip | Director | A | +21,872 deriv. | — |
| 2026-05-18 | Glenn Reicin | CHIEF FINANCIAL OFFICER | A | +164,309 deriv. | — |
| 2026-04-09 | Adam H. Zaeske | CHIEF COMMERCIAL OFFICER | MIXED | +4,327 | −$87.64K |
| 2026-04-06 | Peter Anastasiou | CHIEF OPERATING OFFICER | A | +212,241 deriv. | — |
| 2026-04-06 | Troy A. Ignelzi | Director | A | +17,710 deriv. | — |
| 2026-01-28 | Sandip Kapadia | CHIEF FINANCIAL OFFICER | Sell | −3,746 | −$139.17K |
| 2026-01-26 | Adam H. Zaeske | CHIEF COMMERCIAL OFFICER | A | +73,100 deriv. | — |
| 2026-01-26 | Kumar Budur | CHIEF MEDICAL OFFICER | MIXED | +2,325 | −$92.97K |
| 2026-01-26 | Sandip Kapadia | CHIEF FINANCIAL OFFICER | MIXED | +3,746 | −$176.44K |
| 2026-01-26 | Andrew Serafin | CHIEF STRATEGY OFFICER | MIXED | +2,858 | −$82.55K |
| 2026-01-26 | Jeffrey M. Dayno | PRESIDENT, CEO | MIXED | +13,061 | −$384.36K |
| 2026-01-20 | Sandip Kapadia | CHIEF FINANCIAL OFFICER | Sell | −20,961 | −$752.83K |
| 2025-12-17 | Jeffrey M. Dayno | PRESIDENT, CEO | MIXED | −5,933 | −$875.70K |
| 2025-12-09 | Sandip Kapadia | CHIEF FINANCIAL OFFICER | MIXED | — | −$210.30K |
| 2025-11-25 | Sandip Kapadia | CHIEF FINANCIAL OFFICER | Sell | −3,427 | −$119.94K |
| 2025-10-02 | Sandip Kapadia | CHIEF FINANCIAL OFFICER | MIXED | +20,961 | −$662.51K |
| 2025-09-02 | Valor Equity Capital IV LLC | 10%+ Owner | J | −59,562,297 | — |
| 2025-08-19 | Sandip Kapadia | CHIEF FINANCIAL OFFICER | Sell | −21,573 | −$787.38K |
| 2025-05-16 | Peter Anastasiou | Director | A | +14,522 deriv. | — |
| 2025-05-16 | Linda M Szyper | Director | A | +14,522 deriv. | — |
| 2025-05-16 | R. Mark Graf | Director | A | +14,522 deriv. | — |
| 2025-05-16 | Gary Sender | Director | A | +14,522 deriv. | — |
| 2025-05-16 | Juan A. Sabater | Director | A | +14,522 deriv. | — |
| 2025-05-16 | Antonio J. Gracias | Director | A | +14,522 deriv. | — |
| 2025-05-16 | Ron M Philip | Director | A | +14,522 deriv. | — |
| 2025-05-09 | Kumar Budur | CHIEF MEDICAL OFFICER | MIXED | +9,881 | −$264.83K |
| 2025-04-16 | Adam H. Zaeske | CHIEF COMMERCIAL OFFICER | A | +130,000 deriv. | — |
| 2025-04-04 | Ron M Philip | Director | A | +14,077 deriv. | — |
| 2025-04-03 | Sandip Kapadia | CHIEF FINANCIAL OFFICER | Sell | −6,987 | −$227.39K |
| 2025-04-01 | Sandip Kapadia | CHIEF FINANCIAL OFFICER | MIXED | +6,986 | −$265.98K |
| 2025-03-05 | Jeffrey Dierks | CHIEF COMMERCIAL OFFICER | MIXED | — | −$119.07K |
| 2025-01-28 | Jeffrey M. Dayno | PRESIDENT, CEO | MIXED | +5,933 | −$173.59K |
| 2025-01-28 | Kumar Budur | CHIEF MEDICAL OFFICER | MIXED | +1,036 | −$43.75K |
| 2025-01-28 | Sandip Kapadia | CHIEF FINANCIAL OFFICER | MIXED | — | −$144.97K |
| 2025-01-28 | Jeffrey Dierks | CHIEF COMMERCIAL OFFICER | MIXED | — | −$188.98K |
| 2025-01-28 | Andrew Serafin | CHIEF STRATEGY OFFICER | MIXED | +1,635 | −$32.88K |
| 2025-01-23 | Jeffrey M. Dayno | PRESIDENT, CEO | MIXED | — | −$615.66K |
| 2025-01-23 | Sandip Kapadia | CHIEF FINANCIAL OFFICER | MIXED | — | −$278.85K |
| 2025-01-21 | Jeffrey Dierks | CHIEF COMMERCIAL OFFICER | MIXED | — | −$124.52K |
| 2025-01-16 | Jeffrey Dierks | CHIEF COMMERCIAL OFFICER | MIXED | — | −$37.49K |
| 2025-01-15 | Jeffrey Dierks | CHIEF COMMERCIAL OFFICER | MIXED | — | −$25.85K |
| 2024-11-05 | Marshman Fund Trust II | 10%+ Owner | Sell | −4,600,000 | −$139.39M |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Valor IV Pharma Holdings, LLC | 10%+ Owner | 6,618,033 | $255.52M |
| Marshman Fund Trust II | 10%+ Owner | 6,051,120 | $233.63M |
| Valor Equity Capital IV LLC | 10%+ Owner | 38,275 | $1.48M |
| Sandip Kapadia | CHIEF FINANCIAL OFFICER | 24,521 | $946.76K |
| Kumar Budur | CHIEF MEDICAL OFFICER | 13,915 | $537.26K |
| Jeffrey M. Dayno | PRESIDENT, CEO | 13,000 | $501.93K |
| Jeffrey Dierks | CHIEF COMMERCIAL OFFICER | 4,869 | $187.99K |
| Adam H. Zaeske | CHIEF COMMERCIAL OFFICER | 4,327 | $167.07K |
| Andrew Serafin | CHIEF STRATEGY OFFICER | 2,500 | $96.53K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the HRMY quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.